Prohibits most direct-to-consumer (DTC) advertising for newly approved prescription drugs for the first three years after FDA approval. In year three the FDA may allow a limited advertising waiver if it determines a net public-health benefit; the FDA may later ban advertising for safety reasons and must issue updated regulations within one year of enactment to implement the new rules.